Background Tranexamic acid (TXA) reduces surgical bleeding and reduces death from
bleeding after trauma and childbirth. However, its effects on thrombotic events and seizures …

Tranexamic acid (TXA) is an antifibrinolytic agent commonly used for the treatment or
prevention of bleeding. Indications for TXA are diverse, including heavy menstrual bleeding …

Background Tranexamic acid reduces surgical bleeding and reduces death due to bleeding
in patients with trauma. Meta-analyses of small trials show that tranexamic acid might …

Tranexamic acid (TXA) is a potent antifibrinolytic with documented efficacy in reducing blood
loss and allogeneic red blood cell transfusion in several clinical settings. With a growing …

Background: Although high-bleed surgery routinely utilizes the antifibrinolytic drug
tranexamic acid, most plastic surgical procedures are conducted in soft tissue with low …

Purpose To investigate the incidence rate of tranexamic acid (TXA)-associated seizures.
Methods Two electronic databases (Medline and Embase) were searched. We looked for …

Background It is unclear whether high-dose regimens of tranexamic acid in cardiac surgery
(total dose, 80 to 100 mg/kg) confer a clinical advantage over low-dose regimens (total dose …

The publication of the Clinical Randomization of an Antifibrinolytic in Significant
Hemorrhage-2 (CRASH-2) study and its intense dissemination prompted a renaissance for …

Background: Tranexamic acid (TXA) is an antifibrinolytic drug that reduces surgical blood
loss. Evidence supporting its efficacy in surgery for adolescent idiopathic scoliosis is not …

Inherited and acquired coagulopathy are frequently associated with major bleeding in
severe trauma, cardiac surgery with cardiopulmonary bypass, and postpartum hemorrhage …